Fast-track designation Archives

Tag: Fast-track designation

Lupus Research Alliance Encouraged by Lilly Looking at Potential Lupus Drug for COVID-19

April 23, 2020 The Lupus Research Alliance is pleased to share that Eli Lilly and Company entered into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID) to test the safety and effectiveness of its drug baricitinib as a potential treatment for hospitalized patients with COVID-19. An oral JAK1/JAK2 inhibitor, baricitinib is […] Read More

LRA Salutes RemeGen on FDA Fast-Track Designation for Potential Lupus Treatment

April 16, 2020 The Lupus Research Alliance is pleased to share news that promises to speed up testing and review of a potential new treatment for lupus. The U.S. Food and Drug Administration granted fast-track designation to RC18, in development by a company in China, RemeGen. The FDA defines fast track as “a process designed […] Read More